2 weeks Ago By ABMN Staff
American Century Companies Inc. lifted its holdings in Vanda Pharmaceuticals Inc. ( NASDAQ:VNDA – Free Report ) by 7.
5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 269,971 shares of the biopharmaceutical company’s stock after buying an additional 18,733 shares during the quarter. American Century Companies Inc.
owned approximately 0.46% of Vanda Pharmaceuticals worth $1,525,000 as of its most recent SEC filing. Several other institutional investors also recently bought and sold shares of the company.
Monaco Asset Management SAM bought a new position in shares of Vanda Pharmaceuticals in the 2nd quarter worth approximately $1,090,000. Panagora Asset Management Inc. lifted its stake in shares of Vanda Pharmaceuticals by 4.
3% in the 2nd quarter. Panagora Asset Management Inc. now owns 60,434 shares of the biopharmaceutical company’s stock worth $341,000 after purchasing an additional 2,509 shares during the period.
Bank of New York Mellon Corp lifted its stake in shares of Vanda Pharmaceuticals by 8.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 257,995 shares of the biopharmaceutical company’s stock worth $1,458,000 after purchasing an additional 20,721 shares during the period.
SG Americas Securities LLC bought a new stake in Vanda Pharmaceuticals during the 2nd quarter worth approximately $61,000. Finally, Profit Investment Management LLC raised its stake in Vanda Pharmaceuticals by 159.3% during the 2nd quarter.
Profit Investment Management LLC now owns 571,324 shares of the biopharmaceutical company’s stock worth $3,228,000 after acquiring an additional 351,000 shares during the period. 88.14% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets Several equities research analysts have recently issued reports on VNDA shares. Cantor Fitzgerald lifted their price objective on shares of Vanda Pharmaceuticals from $11.00 to $13.
00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. StockNews.com started coverage on shares of Vanda Pharmaceuticals in a report on Monday.
They issued a “hold” rating for the company. Vanda Pharmaceuticals Price Performance NASDAQ:VNDA opened at $4.67 on Monday.
Vanda Pharmaceuticals Inc. has a 1-year low of $3.30 and a 1-year high of $6.
75. The company has a 50-day moving average of $5.28 and a 200 day moving average of $5.
15. The firm has a market cap of $272.21 million, a PE ratio of -58.
38 and a beta of 0.77. Vanda Pharmaceuticals ( NASDAQ:VNDA – Get Free Report ) last issued its quarterly earnings results on Wednesday, July 31st.
The biopharmaceutical company reported ($0.08) earnings per share for the quarter. Vanda Pharmaceuticals had a negative return on equity of 2.
01% and a negative net margin of 6.00%. The business had revenue of $50.
47 million during the quarter. Sell-side analysts anticipate that Vanda Pharmaceuticals Inc. will post -0.
49 EPS for the current fiscal year. Vanda Pharmaceuticals Company Profile ( Free Report ) Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Read More Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. ( NASDAQ:VNDA – Free Report ).
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter ..
